Recognify Life Sciences

Recognify Life Sciences is a clinical-stage biotechnology company founded in 2018 that is focused on developing pro-cognitive treatment solutions for mental health and neurodegenerative disorders, with a primary emphasis on Cognitive Impairment Associated with Schizophrenia. The company was co-founded by German-American biochemist and Nobel laureat... e Thomas Sudhof, who received the Nobel Prize in Physiology or Medicine in 2013, along with CEO Matt Pando, who brings over 20 years of experience in private and public biotech companies. Recognify develops pharmaceutical therapies that modulate the excitatory and inhibitory balance in the brain to improve learning and memory, with applications for treating cognitive impairment associated with schizophrenia, Alzheimer's disease, and other neurodegenerative and neurocognitive diseases. The company's lead drug candidate, inidascamine, formerly known as RL-007, is a novel GABA and nicotinic modulator that has been tested in multiple clinical trials and exhibits a strong safety profile with acute onset of action and excellent tolerability. In November 2020, ATAI Life Sciences, a Peter Thiel-backed clinical-stage biopharmaceutical company, acquired a majority stake in Recognify in a deal valued in the double-digit millions, making Recognify a strategic investment and subsidiary of ATAI. Recognify operates with a mission to enhance neuroplasticity and impact the quality of life for patients with central nervous system diseases and disorders, addressing significant unmet needs in cognitive impairment treatment.Read More